^




    Show legend
    Group by Gene:
    Include preclinical:

    Aybintio (bevacizumab biosimilar)
    Zirabev (bevacizumab biosimilar)
    		0
    VEGF-A inhibitor
    bevacizumab
    Krabeva (bevacizumab biosimilar)
    Bevax (bevacizumab biosimilar)
    Mvasi (bevacizumab biosimilar)
    cabozantinib tablet
    		1
    Multi-tyrosine kinase inhibitor
    pazopanib
    cabozantinib capsule
    everolimus
    		2
    mTOR inhibitor
    temsirolimus
    sirolimus
    mTOR inhibitor
    nivolumab
    pembrolizumab
    		3
    PD1 inhibitor
    dostarlimab
    toripalimab
    PD1 inhibitor
    4
    IFNα stimulant, VEGF-A inhibitor
    bevacizumab + pegylated interferon α -2a
    Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a
    5
    VEGFR inhibitor, PD1 inhibitor
    pembrolizumab + axitinib
    6
    PD1 inhibitor, CTLA4 inhibitor
    nivolumab + ipilimumab
    7
    PD1 inhibitor, Multi-tyrosine kinase inhibitor
    nivolumab + cabozantinib tablet
    8
    VEGF-A inhibitor, EGFR inhibitor
    bevacizumab + erlotinib
    9
    VEGFR inhibitor, PD-L1 inhibitor
    avelumab + axitinib
    10
    VEGFR inhibitor
    axitinib
    11
    EGFR inhibitor
    erlotinib
    12
    HIF-2α inhibitor
    belzutifan
    PT2385
    13
    ALK inhibitor
    crizotinib
    alectinib
    14
    c-MET inhibitor
    savolitinib
    c-MET inhibitor
    atezolizumab
    		15
    PD-L1 inhibitor
    avelumab
    PD-L1 inhibitor
    16
    PARP inhibitor
    olaparib
    17
    HDAC inhibitor, Multi-tyrosine kinase inhibitor
    pazopanib + CG-781
    18
    BRAF inhibitor
    vemurafenib
    19
    VEGF-A inhibitor, PI3Kγ inhibitor, Tubulin inhibitor
    bevacizumab + albumin-bound paclitaxel + IPI-549
    20
    FGFR inhibitor
    ABSK-091
    21
    VEGFR inhibitor, mTOR inhibitor
    temsirolimus + axitinib
    22
    PD1 inhibitor, IDO1 inhibitor
    nivolumab + BMS-986205
    pembrolizumab + INCB024360
    23
    mTORC1 inhibitor, mTORC2 inhibitor
    TAK-228
    24
    ALK inhibitor, Multi-tyrosine kinase inhibitor
    crizotinib + pazopanib
    25
    VEGFR-2 inhibitor, c-MET inhibitor
    GSK1363089
    26
    VEGFR inhibitor, PDGFR inhibitor, c-KIT inhibitor
    sunitinib
    27
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, c-KIT inhibitor, PDGFR α antagonist
    lenvatinib
    28
    VEGFR-2 inhibitor, RAF kinase inhibitor, BRAF inhibitor, PDGFR β antagonist
    sorafenib
    29
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PD1 inhibitor, c-KIT inhibitor, PDGFR α antagonist
    pembrolizumab + lenvatinib
    30
    VEGFR-3 antagonist, VEGFR-2 inhibitor, VEGFR-1 antagonist
    tivozanib
    31
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, mTOR inhibitor, c-KIT inhibitor, PDGFR α antagonist
    everolimus + lenvatinib
    32
    CD122 agonist, IL-2 stimulant
    aldesleukin
    33
    PD-L1 inhibitor, VEGF-A inhibitor
    bevacizumab + atezolizumab
    34
    CDK4 inhibitor, CDK6 inhibitor
    palbociclib
    35
    PD-L1 inhibitor, VEGF-A inhibitor, PI3Kγ inhibitor
    bevacizumab + atezolizumab + IPI-549
    36
    TIM-1-targeted antibody-drug conjugate, Microtubule inhibitor
    CDX-014
    37
    VEGFR inhibitor, PDGFR inhibitor, Multi-tyrosine kinase inhibitor, c-KIT inhibitor
    sunitinib + pazopanib
    38
    VEGFR-2 inhibitor, RAF kinase inhibitor, Hyaluronic acid synthase inhibitor, BRAF inhibitor, PDGFR β antagonist
    sorafenib + 4-methylumbelliferone
    39
    PRC2 inhibitor
    MRTX2219
    40
    MEK2 inhibitor, MEK1 inhibitor
    U0126
    41
    RAC1 inhibitor
    NSC23766
    42
    Topoisomerase II inhibitor
    doxorubicin hydrochloride
    43
    VEGFR inhibitor, PDGFR inhibitor, VEGFR-2 inhibitor, RAF kinase inhibitor, BRAF inhibitor, c-KIT inhibitor, PDGFR β antagonist
    sorafenib + sunitinib
    44
    CYP17A1 inhibitor
    abiraterone acetate
    45
    DNA synthesis inhibitor
    cisplatin
    46
    Glutamate inhibitor
    Glutamate inhibitor
    47
    Immunotherapy
    Immunotherapy
    48
    Tyrosine kinase inhibitor
    Tyrosine kinase inhibitor
    49
    VEGF inhibitor
    VEGF inhibitor
    No biomarker
    PD-L1 expression
    PD-L1 underexpression
    PD-L1 overexpression
    MET mutation
    MET amplification
    MET fusion
    KDR rs2071559
    KDR C482R
    KDR expression
    MTOR mutation
    FLT1 rs9554320
    PBRM1 mutation
    PBRM1 overexpression
    PBRM1 deletion
    FLT1 expression
    PBRM1 negative
    MTOR Q2223K
    PBRM1 underexpression
    ARID1A mutation
    ROBO3 mutation
    AXL-L
    AXL overexpression
    AXL expression
    VHL mutation
    ALK rearrangement
    PD-1 expression
    HGF expression
    TSC1 mutation
    TSC2 mutation
    TSC1 deletion
    TSC2 H1620R + TSC2 Y1650C
    HMOX1 expression
    HGF-L
    HMOX1-L
    VHL promoter methylation
    HGF-H
    PD-1-H
    FH mutation
    TIMP1 expression
    CSF1 expression
    VEGFA expression
    CXCL9 expression
    IL18BP expression
    SYNE1 mutation
    ERVE-4 expression
    CDKN2A mutation
    CEACAM1 overexpression
    CXCL10 overexpression
    CA9 expression
    CD31 expression
    GNAQ mutation
    IKZF2-L
    KDM5C mutation
    PDGFRA expression
    HDAC2 expression
    CD8 expression
    HIF1A expression
    TFE3 translocation
    FLCN mutation
    LRP1B mutation
    ELTD1 expression
    KIM1 expression
    BRCA2 mutation
    BRCA1 mutation
    BAP1 negative
    IL6R L
    IL6-L
    IL6ST-H
    TFEB translocation
    EWSR1-POU5F1 fusion
    KMT2C mutation
    LDH elevation
    CTLA4 promoter hypomethylation
    NANOGNB mutation
    ANGPT2 expression
    PBRM1 mutation + SETD2 mutation
    TERT promoter mutation
    BRAF mutation
    miR138 underexpression + miR497 overexpression
    HAVCR2 expression
    SPP1-L
    CXCL8-L
    IL18 expression
    IL6-H
    CXCL8 elevation
    BAP1 mutation
    CXCL10-H
    VEGFA-H
    BAP1 deletion
    KIM1 elevation
    IL6 elevation
    CDKN2A deletion
    TERT overexpression
    FLCN deletion
    T-cell-inflamed GEP signature
    IFNG gene signature overexpression
    DDR
    Tregs-H
    MSI-H/dMMR
    NT5E overexpression
    Chr del(9)(p21.3)
    TP53 expression
    HAS3 expression
    FGFR1 overexpression
    DAPK1 underexpression
    miR-155 underexpression
    SMARCA4 mutation
    KDM6A mutation
    PTTG1 overexpression
    TP53 mutation
    MCAM overexpression
    PLK1 overexpression
    CCNE1 amplification
    CTBP1 deletion
    LAG3 expression
    ACRBP amplification
    CXCL11-H
    CCL4 elevation
    DDX39B overexpression
    ADCYAP1 deletion
    AXL overexpression + PD-L1 expression
    GNAS amplification
    LRP10 deletion
    CXCL13 elevation
    TNFSF13B elevation
    UGT1A9 expression
    SULT1A3 amplification
    PAI1-H
    IL13RA2 overexpression
    CXCL12-H
    CXCR4 overexpression
    SETD2 mutation
    AR-V7 positive
    EPAS1 overexpression